Signal Genetics (SGNL) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Signal Genetics Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2015 Financial Results
March 16, 2016 4:05 PM EDTCARLSBAD, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ: SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2015.
Recent Highlights
Record Volume of MyPRS® Tests Sold, Increasing 131% 4Q-over-4Q, to customers outside of the University of Arkansas for Medical Sciences (UAMS)Entered into Sponsored Research... More